



CORPORATE UPDATE

TSXV: **VPT** | OTCQB: **VPTDF**

May 2023

FORWARD LOOKING STATEMENTS

Ventripoint Diagnostics Disclaimer The information in this presentation may include forward-looking statements related to our future growth, trends in our industry, our financial and or operational results, and our financial or operational performance. Such forward-looking statements are predictive in nature, and may be based on current expectations, forecasts or assumptions involving risks and uncertainties that could cause actual outcomes and results to differ materially from the forward-looking statements themselves. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”, or similar expressions, or may employ such future or conditional verbs as “may”, “will”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. For these statements, we claim the protection of the safe harbour for forward-looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. The risks and uncertainties referred to above include, but are not limited to: variability of operating results among periods; inability to retain or grow our business due to execution problems resulting from significant headcount reductions, plant closures and product transfer associated with major restructuring activities; the effects of price competition and other business and competitive factors generally affecting the EMS industry; the challenges of effectively managing our operations during uncertain economic conditions; our dependence on a limited number of customers; our dependence on industries affected by rapid technological change; the challenge of responding to lower-than-expected customer demand; our ability to successfully manage our international operations; and delays in the delivery and/or general availability of various components used in the manufacturing process. These and other risks and uncertainties and factors are discussed in the Company’s various public filings at www.sedar.com and www.sec.gov, including our Form 20-F and subsequent reports on Form 6-K filed with the Securities and Exchange Commission. Except as required by applicable law, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



MISSION: Improving the Lives of Patients

To improve the lives of patients by providing clinicians with the tools they need to deliver improved patient care, experiences, and outcomes. We aim to become the standard of care.

VISION: To elevate cardiac care

The technology was founded on a heartfelt desire to find a better way to provide care to children without relying on the highly restrictive MRI and still providing doctors with complete and full information that they need to monitor the heart state and make a confident diagnosis and treatment decisions.



Where we are today



Global install base in leading hospitals

Endorsement by leading cardiologists that will influence adoption in their region



Happy customers

Value delivered to clinicians and patients



Established resources and infrastructure

Expanded our sales, marketing, and servicing teams




Expanded product distribution in North America, UK, and Europe

Team of strategic sales leaders, clinical applications specialists, technical support, support engineers, customer support

33 representatives covering all territories



KEY MARKET SEGMENT



TARGET GEOGRAPHIES



CHANNELS

➔ Direct Sales:

Team of Strategic sales leaders, clinical applications specialists, service engineers, and technical support personnel

➔ Distributor:

Distributors in United States, Europe, and the United Kingdom who sell “complimentary” cardiology products from other manufacturers to provide a broader category of ancillary products to the end user

33 sales representatives covering all our target markets




OUR SALES STRATEGY

- ➔ Clinical evaluations for 3-5 days with clinical applications specialist and triage of complex case patients
- ➔ Work with the sonographers so that they can see how VMS+ integrates into typical workflow
- ➔ Work with administrators to start the process for purchase



OUR SALES PROCESS



STATUS OF GROWTH STRATEGIES

- ➔ Broaden leadership in the CHD market and then expand into other market segments
- ➔ Focus on expanding into new user segments
- ➔ Accelerating integration into OEM and becoming standard of care





HAVE QUESTIONS?

**GET IN TOUCH WITH VENTRIPOINT
DIAGNOSTICS LTD.**

www.ventripoint.com

INVESTOR RELATIONS

Jonathan L. Robinson, CFA
Partner

Oak Hill Financial Inc.

Telephone: (416) 669-1001

E-mail : JRobinson@oakhillfinancial.ca